Form 10-K Dianthus Therapeutics, For: Dec 31
Dianthus Therapeutics, Inc. (DNTH)
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
DNTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DNTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DNTH alerts
High impacting Dianthus Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
DNTH
News
- Dianthus Therapeutics, Inc. (NASDAQ: DNTH) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $36.00 price target on the stock.MarketBeat
- Dianthus Therapeutics, Inc. (NASDAQ: DNTH) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $84.00 price target on the stock.MarketBeat
- Dianthus Therapeutics, Inc. (NASDAQ: DNTH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.MarketBeat
- Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial ResultsGlobeNewswire
- Dianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango, A Seasoned Commercial Leader, to Board of Directors [Yahoo! Finance]Yahoo! Finance
DNTH
Earnings
- 8/8/24 - Miss
DNTH
Sec Filings
- 3/11/25 - Form S-8
- 3/11/25 - Form 8-K
- 3/5/25 - Form 4
- DNTH's page on the SEC website